Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Nitric Oxide in Mechanically Ventilated COVID-19 Patients
2020-001490-68Phase 2Completed
- Sponsor
- Region Stockholm
- Start
- Apr 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of nitric oxide in coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS) and Airways Infection (2 arms), sponsored by Region Stockholm. Primary endpoint: Duration of mechanical ventilation until successful extubation. Started Apr 2020; status: completed.
02
Drugs
nitric oxide
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)Airways Infection
Beyond the preview
Go deeper on 2020-001490-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001490-68.